Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Verastem, Inc. (VSTM) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including Forms 8-K, 10-K, 10-Q, and registration statements filed with the U.S. Securities and Exchange Commission. Verastem’s filings document its status as a Nasdaq-listed biopharmaceutical issuer focused on RAS/MAPK pathway-driven cancers, with common stock registered on The Nasdaq Capital Market under the symbol VSTM.
Recent Form 8-K reports highlight several important areas for investors: underwritten public offerings of common stock and pre-funded warrants under an effective shelf registration statement on Form S-3, preliminary and updated clinical data for the KRAS G12D inhibitor VS-7375, and company communications regarding AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. These current reports also reference updated corporate presentations and conference materials that outline Verastem’s pipeline and strategy.
For a biopharmaceutical company like Verastem, periodic reports such as Forms 10-K and 10-Q (when available) typically contain detailed information on research and development spending, commercialization activities for AVMAPKI FAKZYNJA CO-PACK, risk factors related to oncology drug development, and the status of key clinical programs such as RAMP 301, RAMP 205, and VS-7375-101. Capital structure changes, including equity offerings and warrant terms, are also described in registration statements and accompanying exhibits.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain complex sections in plain language, highlight material events, and surface items of interest such as financing transactions, clinical trial disclosures, and changes in capital markets activity. Users can quickly scan new 8-Ks, 10-Qs, and 10-Ks for Verastem, review details of public offerings and warrant structures, and explore how regulatory filings align with the company’s oncology pipeline and commercial strategy.
Verastem, Inc. (VSTM) – Form 4 insider activity
President & Chief Executive Officer Dan Paterson filed a Form 4 disclosing the sale of 17,808 common shares on 20-Jun-2025 at $5.13 per share. The transaction was coded “S,” and the filing states that the sale was made solely to cover statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs).
After the withholding-related sale, Paterson’s direct beneficial ownership stands at 443,839 common shares. No derivative securities were bought or sold, and there were no Rule 10b5-1 trading-plan indications.
Key take-aways for investors
- The transaction value is approximately $91,400, representing a small fraction of his total equity stake.
- The filing cites administrative tax obligations rather than discretionary profit-taking, which typically lessens negative signaling.
- No changes were reported to option holdings, RSUs, or indirect ownership.
Because the CEO retains a substantial position and the sale size is modest relative to both his holdings and Verastem’s market capitalization, the market impact is expected to be immaterial. Nonetheless, investors monitoring insider sentiment should log the event for longitudinal trend analysis.
Verastem, Inc. (VSTM) – Form 4 insider transaction summary
Chief Financial Officer Daniel Calkins filed a Form 4 reporting two open-market sales of Verastem common stock:
- 06/20/2025: 4,110 shares sold at $5.13 per share.
- 06/23/2025: 25 shares sold at $4.71 per share.
The filing explains that the transactions were executed solely to cover statutory tax-withholding obligations triggered by the vesting of previously granted restricted stock units (RSUs). No derivative securities were involved in this report.
Following the sales, Calkins’ direct beneficial ownership stands at 109,945 common shares. The disposition represents roughly 3.6 % of his previously reported direct holdings, leaving the executive with a substantial equity position that continues to align his interests with shareholders.
No additional purchases, option exercises, or new awards were disclosed, and there is no indication of a 10b5-1 trading plan for these transactions. Because the sales were relatively small and explained as tax-related, the market impact is expected to be limited; however, investors often track insider activity for sentiment cues, and any sale by a senior officer can attract attention.
Verastem, Inc. (VSTM) Form 4 filing: On 06/16/2025, President & CEO and director Dan Paterson reported the sale of 335 shares of Verastem common stock at $5.65 per share. The transaction code “S” indicates an open-market sale, but the footnote clarifies that the shares were sold solely to satisfy statutory tax-withholding obligations arising from recently vested restricted stock units (RSUs).
Following the small disposition, Paterson’s direct ownership stands at 461,647 shares. The sale represents less than 0.1 % of his post-transaction holdings, suggesting no meaningful change in his economic exposure to the company. No derivative security transactions were reported, and there were no indications of additional sales or purchases under a Rule 10b5-1 trading plan. Overall, the filing signals routine administrative activity rather than a strategic shift in insider sentiment.
SEC Form 4 overview – Verastem, Inc. (VSTM)
On 06/16/2025 director Robert E. Gagnon reported the disposition of 284 common shares at $5.65 per share, an aggregate value of roughly $1.6 thousand. The sale was executed solely to satisfy statutory tax-withholding requirements related to the vesting of restricted stock units, according to the filing’s footnote. After the transaction Gagnon directly owns 42,242 shares; no derivative securities were traded or reported. Because the sale represents less than 1% of his holdings and is administrative in nature, the filing signals minimal change in insider alignment and no operational impact on Verastem.